Strides Pharma Science Ltd
NSE:STAR

Watchlist Manager
Strides Pharma Science Ltd Logo
Strides Pharma Science Ltd
NSE:STAR
Watchlist
Price: 655.2 INR -3.95%
Market Cap: 60.4B INR

Strides Pharma Science Ltd
Investor Relations

Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.

Show more
Loading

Earnings Calls

2025 Q3
Feb 7, 2025
Show Transcript
Previous
Next
Graham Corporation Reports Strong Growth and Strategic Initiatives in Q3 Earnings Call
2025 Q3
Feb 7, 2025

In the third quarter, Graham Corporation achieved $47 million in sales, growing 7.3% year-over-year, driven by key sectors like defense, which rose 11%. Gross margins improved to 24.8%, benefiting from better execution and pricing. Adjusted EBITDA surged 36% to $4 million. Looking forward, the company anticipates fiscal 2025 revenue between $200 million and $210 million, reflecting an 11% growth. Adjusted EBITDA is expected to reach $18 million to $21 million, equating to a 9.5% margin. Graham also aims for an organic growth rate of 8% to 10% annually through strategic investments and acquisitions.

Show Full Analysis

Management

Mr. Arun Kumar Pillai B.Com.
Founder & Executive Chairperson
No Bio Available
Mr. Badree Komandur
MD & Group CEO
No Bio Available
Ms. Manjula Ramamurthy
Compliance Officer & Company Secretary
No Bio Available
Mr. Aditya Arun Kumar
Executive Director of Business Development & Director
No Bio Available
Mr. Vikesh Kumar
Group CFO & Chief Investor Relations Officer
No Bio Available
Mr. P. V. S. Ramaraju
Chief Operating Officer
No Bio Available
Sormistha Ghosh
Group General Counsel, Chief Risk Officer & Chief Sustainability Officer
No Bio Available
Ms. Surabhi Loshali
Group Chief Human Resource Officer
No Bio Available
Mr. C. K. Sundar
Executive Vice President of Operations
No Bio Available
Mr. Kevin P. Cook
Senior Vice President of Strides Pharma Inc.
No Bio Available

Contacts

Address
KARNATAKA
Bangalore
Strides House, Bannerghatta Road, Bilekahalli
Contacts
+918067840000
www.strides.com